Bristol Myers Squibb, Immunocore Holdings ink pact to evaluate IMC-F106C, nivolumab combo in registrational Phase 3 first-line advanced cutaneous melanoma trial

Under the terms of the collaboration, Immunocore will sponsor and fund the registrational Phase 3 clinical trial of IMC-F106C in combination with nivolumab in first-line advanced cutaneous melanoma (PRISM-MEL-301), and Bristol Myers Squibb will provide nivolumab.

The PRISM-MEL-301 trial will randomize HLA-A*02:01+ first-line advanced cutaneous melanoma patients to IMC-F106C + nivolumab versus a control arm of either nivolumab or the fixed-dose combination of nivolumab and relatlimab, depending on the country where the patient is enrolled. Immunocore plans to randomize the first patient in this trial in the first quarter of 2024.

Read also: USFDA accepts for priority review Bristol Myers Squibb application for Krazati, cetuximab combo for colorectal cancer

Immunocore is a commercial-stage biotechnology company developing a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease.

Read also: CDSCO Panel grants Bristol Myer Squibb's Proposal for Additional Indication of anti-cancer drug Nivolumab

The Company is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs.

The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

Read also: Bristol Myers Squibb application for Augtyro for NTRK-Positive Locally Advanced or Metastatic Solid Tumors accepted by USFDA for priority review